Does having some ability to create insulin in type 1 diabetes help protect circulating cells that repair blood vessels and result in different immune responses, and does this work in combination with exercise?

Does residual ß-cell function and exercise offer synergistic protection against hyperglycaemic induced circulating vasoprotective dysfunction and immune deficiency in type 1 diabetes?

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11671196

Enrollment

Registered

2022-06-06

Start date

2022-06-15

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Individuals with type 1 diabetes and varying levels of residual beta-cell function Nutritional, Metabolic, Endocrine

Interventions

Ten participants with type 1 diabetes (T1D) and undetectable C-peptide (0.100 nmol/mmol) , and 10 non-diabetes controls will be recruited. Type 1 diabetes participants will be identified using urinary

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals with T1D: 1. Willing and able to provide informed consent 2. Aged 18 to 50 years old 3. Clinical diagnosis and classic presentation of T1D (primary osmotic symptoms, weight loss, hyperglycemia, ketosis, insulin initiation at diagnosis) 4. T1D diagnosis for =2 years Non-diabetes controls: 1. Willing and able to provide informed consent 2. Aged 18 to 50 years old 3. No history of any chronic disease

Exclusion criteria

Exclusion criteria: Individuals with T1D: 1. Participation in another research study 2. Aged >50 years or 70 mmol/mol Non-diabetes controls: 1. Participation in another research study 2. Aged >50 years or <18 years 3. Any sign/symptom of cardiovascular, metabolic or renal disease 4. Previous or current diagnosis of a chronic disease, including but not limited to, cardiovascular disease (myocardial infarction or stroke), diabetes and cancer 5. Fasting blood glucose =5.5 mmol/L 6. Resting hypertension (=160 mmHg systolic and/or =90 mmHg diastolic) 7. Respiratory disease with peak respiratory flow <300 l/min 8. Previous stroke 9. Pregnancy 10. Irregular period 11. Hormonal treatment for menopause 12. Currently on any medication that may influence angiogenic cells or leukocytes, including Statins, NSAID, Opioids, Antihypertensives and Antibiotics 13. Unable to read and understand the instructions provided in English 14. Contraindication to venous blood sampling 15. Unwilling to undertake exercise 16. Smoker

Design outcomes

Primary

Measure	Time frame
Measured at a single time point: 1. Apoptosis (measured by flow cytometry) of EPCs grown in high glucose condition. 2. Count of leucocyte cells (measured by flow cytometry) within the peripheral blood.	—

Secondary

Measure	Time frame
Measured at a single time point: 1. Function of EPCs (measured by scratch and proliferation assays) grown in high glucose. 2. Responsivity to stimulus (pancreatic proteins) of white blood cell populations as measured by ELISpot.	—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026